Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | MLYCD | O95822 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6990995 | 0.86 | KMT2A (0.54) | MEN1KMT2A | |
| SCHEMBL6991167 | 0.76 | PIN1 (0.52) | MEN1KMT2ANPC1 | |
| SCHEMBL6989665 | 0.76 | NPC1 (0.40) | NPC1 | |
| SCHEMBL5645193 | 0.73 | MEN1 (0.78) | MEN1KMT2AMTORMLYCDTACR1 | |
| SCHEMBL6987408 | 0.73 | MLYCD (0.51) | MLYCD | |
| SCHEMBL6989399 | 0.72 | ALDH1A1 (0.40) | KMT2A | |
| SCHEMBL6885455 | 0.70 | MEN1 (0.42) | MEN1KMT2AMTORMLYCDTACR1 | |
| SCHEMBL5643054 | 0.70 | KMT2A (0.68) | MEN1KMT2AMTORMLYCD | |
| SCHEMBL7390057 | 0.70 | MTOR (0.55) | MEN1KMT2AMTORMLYCDTACR1 | |
| SCHEMBL5641801 | 0.69 | MEN1 (0.67) | MEN1KMT2AMTORMLYCDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | FABP4, FABP1, FABP3 | MEN1 4880/4885KMT2A 4481/4885MTOR 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.